Reuters logo
BRIEF-Genmab expects royalties of 31 mln DKK in Q3
October 23, 2013 / 11:17 AM / 4 years ago

BRIEF-Genmab expects royalties of 31 mln DKK in Q3

COPENHAGEN, Oct 23 (Reuters) - Danish biotech firm Genmab said on Wednesday:

* Net sales of blood cancer drug Arzerra (ofatumumab) during the third quarter of 2013 were 17.8 million GBP

* Expects to receive a royalty payment of approximately 31 million Danish crowns ($5.72 million) from its partner British GlaxoSmithKline Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below